Micraleve

Micraleve Uses, Dosage, Side Effects, Food Interaction and all others data.

An anthracenedione-derived antineoplastic agent.

Micraleve has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2.

Trade Name Micraleve
Availability Prescription only
Generic Mitoxantrone
Mitoxantrone Other Names Mitoxantrona, Mitoxantrone, Mitoxantronum
Related Drugs Gilenya, Tysabri, Vumerity, methotrexate, estradiol, Premarin, rituximab, Rituxan, cyclophosphamide, Xtandi
Type
Formula C22H28N4O6
Weight Average: 444.4809
Monoisotopic: 444.200884648
Protein binding

78%

Groups Approved, Investigational
Therapeutic Class
Manufacturer
Available Country Argentina
Last Updated: September 19, 2023 at 7:00 am
Micraleve
Micraleve

Uses

Micraleve is a chemotherapeutic agent used for the treatment of secondary progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis.

For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis

Micraleve is also used to associated treatment for these conditions: Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia (APL), Lymphoma, Hodgkins, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma, Allogeneic peripheral haematopoietic stem cell transplant

How Micraleve works

Micraleve, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Micraleve also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. It has a cytocidal effect on both proliferating and nonproliferating cultured human cells, suggesting lack of cell cycle phase specificity.

Toxicity

Severe leukopenia with infection.

Food Interaction

No interactions found.

Volume of Distribution

  • 1000 L/m2

Elimination Route

Poorly absorbed following oral administration

Half Life

75 hours

Clearance

  • 21.3 L/hr/m2 [Elderly patients with breast cancer receiving IV administration of 15-90 mg/m2]
  • 28.3 L/hr/m2 [Non-elderly patients with nasopharyngeal carcinoma receiving IV administration of 15-90 mg/m2]
  • 16.2 L/hr/m2 [Non-elderly patients with malignant lymphoma receiving IV administration of 15-90 mg/m2]

Innovators Monograph

You find simplified version here Micraleve

*** Taking medicines without doctor's advice can cause long-term problems.
Share